stated that he “firmly believes that the repurposing of FDA-approved drugs with demonstrated anti-ageing potential represents a highly promising and cost-effective approach to addressing the ...
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.